View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 13, 2018

Deals this week: Dr. Reddy’s Laboratories, Pluristem Therapeutics, Fortress Biotech

Dr. Reddy's Laboratories has signed a distribution agreement with UCB to supply the latter’s epilepsy drug Briviact in India.

Dr. Reddy’s Laboratories has signed a distribution agreement with UCB to supply the latter’s epilepsy drug Briviact in India.

As part of the agreement, Dr. Reddy’s will receive the exclusive right to distribute Briviact in India.

Briviact is a brand of brivaracetam, which is indicated for the treatment of partial-onset seizures in epilepsy patients aged 16 years and above.

Based in India, Dr. Reddy’s Laboratories is a pharmaceutical company that provides novel medicines, while UCB is a Canada-based biopharmaceutical company engaged in the research and development of medicines for epilepsy, Parkinson’s and Crohn’s diseases.

Pluristem Therapeutics has signed an agreement with Thermo Fisher Scientific for the co-development of cell therapy industrialisation and to enhance quality control.

The two companies intend to scale up the manufacturing of regenerative medicines, through the collaboration.

Based in Israel, Pluristem is engaged in the development of placenta-based cell therapy products, while Thermo Fisher is a US-based biotechnology company focused on the development of lab equipment and reagents.

The agreement enables both companies to expand cell therapy production of regenerative medicines.

“Fortress Biotech plans to raise $50m through an initial public offering of shares.”

Fortress Biotech plans to raise $50m through an initial public offering of shares.

The company intends to offer and sell the securities periodically in the form of common stock, preferred stock, debt securities, and warrants.

Alston & Bird has been appointed as legal adviser to Fortress for the offering.

Based in the US, Fortress Biotech is a biopharmaceutical company that develops novel pharmaceuticals.

Boehringer Ingelheim has signed an asset transaction agreement with MabVax Therapeutics for the rights to the latter’s antibody development programme for solid tumours.

Boehringer will acquire all the rights to MabVax’s programme and MabVax will receive $11m in upfront and milestone payments from the company, under the deal.

The asset acquisition does not include Boehringer to purchase other programmes being developed by MabVax.

Based in Germany, Boehringer is a pharmaceutical company focused on the development of pharmaceuticals for metabolism, immunology and oncology-related diseases, while MabVax is a US-based biotechnology company focused on the discovery of human antibodies for the treatment of cancer.

The agreement enables MabVax to develop and discover innovative antibodies for the treatment of cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU